Key Developments For Masimo Corporation
Masimo Corporation (MASI.O) (Nasdaq)
Masimo Corporation Announces Advocate Health Care Renews Multi-Year, System-Wide Contract For Masimo SET Pulse Oximetry Technology
Masimo Corporation announced that Advocate Health Care, has renewed its multi-year, system-wide contract for Masimo SET pulse oximetry technology. A Masimo customer since 2001, Advocate Health Care's renewal of its Masimo SET technology standardization contract means Masimo will continue to support the pulse oximetry needs of more than 200 Advocate sites of care across metropolitan Chicago.
Uni.H.A. Signs Purchasing Agreement for Masimo Corporation's Masimo SET Pulse Oximetry Products
Masimo Corporation announced that Lyon, France-based Uni.H.A., one of the healthcare Group Purchasing Organizations (GPO) in France, has signed a multi-year purchasing agreement for gold standard Masimo SET pulse oximeters. The agreement offers preferred contract pricing to Uni.H.A.'s 53 member hospitals and provides for more than 1,000 Masimo SET bedside pulse oximeters and 650 handheld pulse oximeters to be purchased within four-years.
CareFusion Corporation Signs Multi Year Technology Licensing Agreement With Masimo Corporation For Masimo Rainbow SET Pulse CO-Oximetry
Masimo Corporation and CareFusion Corporation announced a multi-year technology licensing agreement establishing noninvasive blood constituent monitoring capabilities of Masimo Rainbow SET Pulse CO-Oximetry technology to be used in CareFusion infusion and respiratory products under development. Incorporating Masimo Rainbow SET Pulse CO-Oximetry technology will enable CareFusion's future infusion and respiratory products (under development) to noninvasively and continuously measure multiple blood constituents to more accurately assess dyshemoglobins affecting oxygenation, predict fluid responsiveness, and provide earlier identification of respiratory compromise.
Masimo Corporation Announces New Published Study Shows Masimo Rainbow SET Pulse CO-Oximetry Reliably Determines Carbon Monoxide Levels in the Blood
Masimo Corporation announced that a new peer-reviewed clinical study published in this month's Inhalation Toxicology demonstrates that Masimo Rainbow SET Pulse CO-Oximetry (SpCO) provides reliable measurements of carbon monoxide (CO) in the blood that facilitate fast, accurate diagnosis of CO poisoning in pre-hospital emergency and rescue environments. Carbon monoxide - often called the silent killer - is a colorless, odorless, tasteless, and deadly gas that is extremely difficult to detect. Prior to Masimo Rainbow SET Pulse CO-Oximetry, an invasive blood draw followed by laboratory blood gas analysis was the only reliable method for diagnosing CO poisoning. Without immediate access to complex and costly laboratory blood analyzers to measure CO in the blood (COHb), emergency first responders were at a critical disadvantage - unable to confirm the diagnosis of CO poisoning necessary to initiate appropriate, often lifesaving treatment. Today, the portable, handheld Masimo Rad-57 Pulse CO-Oximeter provides an accurate and noninvasive way to detect elevated CO levels in the bloodstream in just seconds - allowing emergency first responders to quickly and easily diagnose CO poisoning on-the-scene and initiate prompt, possibly lifesaving treatment.
Masimo Corporation Announces Federal Court of Appeals Upholds Antitrust Liability Verdict Against Tyco Healthcare Now Covidien plc
Masimo Corporation announced that the Ninth Circuit Court of Appeals has affirmed the 2006 Federal District Court decision that Tyco Healthcare, now Covidien plc, violated the antitrust laws through anticompetitive business practices related to the sale of its Nellcor pulse oximetry products. The 2006 decision found that Tyco had unlawfully maintained monopoly power in violation of Section 2 of the Sherman Act, and that Tyco's sole-source agreements and market-share based compliance pricing contracts were unlawful restraints of trade in violation of Section 1 of the Sherman Act and unlawful exclusionary dealing arrangements in violation of Section 3 of the Clayton Act. The Ninth Circuit also held that above-cost bundling discounts when combined with sole-source or market-share-based pricing can be anticompetitive when such practices involve a significant portion of the market. The suit was originally filed by Masimo in 2002.
